BusinessNeos Therapeutics Announces US Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years OldBy Nasdaq OMXOct 2, 2017, 12:01 PM UTC
BusinessNeos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and OlderBy Nasdaq OMXSep 15, 2017, 8:39 PM UTC
BusinessNeos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years OldBy Nasdaq OMXSep 5, 2017, 12:00 PM UTC
BusinessNeos Therapeutics to Participate in Three September ConferencesBy Nasdaq OMXAug 30, 2017, 11:30 AM UTC
BusinessNeos Therapeutics Reports Second Quarter 2017 Financial ResultsBy Nasdaq OMXAug 8, 2017, 11:01 AM UTC
BusinessNeos Therapeutics to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017By Nasdaq OMXAug 2, 2017, 11:30 AM UTC
BusinessNeos Therapeutics Announces Proposed Offering of Common StockBy Nasdaq OMXJun 26, 2017, 8:02 PM UTC
BusinessNeos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years OldBy Nasdaq OMXJun 20, 2017, 1:47 AM UTC
